← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 72.5% to $7.1M, while Net income increased 67.7% to ($20.6M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $7.1MWatch
- Profitability — Net income ($20.6M)Watch
- Cash generation — Free cash flow ($98.0M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality weakWatch
- Insiders — 0 buys; 14 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Whitehawk Therapeutics, Inc.: We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.
Where the revenue comes from
Fiscal 2025, as Whitehawk Therapeutics, Inc. reports it. History and quarterly detail are in the app.
Leadership changes
From Whitehawk Therapeutics, Inc.'s own filings, the day they're filed.
- Baiteng Zhao · director · appointmenteff. 2024-12-19
- Loretta Itri · Chief Medical Officer · departureeff. 2024-10-01
- Neil Desai · Chairman · departureeff. 2024-08-20
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Whitehawk Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.